CompletedInterventionalPhase 1Last updated Jul 6, 2007

Bioequivalence Trial of a New Opioid Combination Compared to Reference

Phase 1 Single Center Trial to Demonstrate the Bioequivalence of a New Combination Analgesic Formulation as Compared to an Equimolar Marketed Formulation

Overview

ClinicalTrials.gov ID: NCT00460785
Lead Sponsor: Grünenthal GmbHINDUSTRY
Brief Summary: The purpose of this study is to demonstrate bioequivalence of a new formulation to a reference
Study Type: Interventional

Status

Overall Status: Completed
Start Date: Feb 2007
Primary Completion Date: No data available
Completion Date: Mar 2007Actual

Study Record Dates

First Submitted: Mar 28, 2007
First Submitted that Met QC Criteria: Apr 13, 2007
First Posted: Apr 16, 2007Estimated
Last Update Submitted that Met QC Criteria: Jul 5, 2007
Last Update Posted: Jul 6, 2007Estimated
Last Verified: Mar 2007

NCT00469404Terminated

Single Dose Trial Comparing the Plasma Levels of Two Different Analgesic Transdermal Patch Formulations (Protocol ID 297307)

NCT00388219Terminated

Single Dose Trial Comparing the Plasma Levels of Two Different Analgesic Transdermal Patch Formulations

NCT00469053Terminated

Multiple Dose Trial Comparing the Plasma Levels of Two Different Analgesic Transdermal Patch Formulations (Protocol ID: 855509)

NCT00387777Terminated

Multiple Dose Trial Comparing the Plasma Levels of Two Different Analgesic Transdermal Patch Formulations

NCT02089581Completed

A Study of Whether 2 New Oral Formulations of a Strong Pain Killer Release the Same Amount of Drug Into the Body as the Marketed Medication

NCT02446561Completed

A Study of Whether 3 New Oral Formulations of a Strong Pain Killer Release the Same Amount of Drug Into the Body as the Marketed Medication